Fig. 3From: Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trialAnalysis of categorical change from baseline to week 48 by CFQ-R scale and treatment group. *p-value < 0.05. from chi-square test for differences between treatment groups in the percentage of “improvement”, “no change” and “decline” patientsBack to article page